CompletedPhase 2NCT00003283
Octreotide With or Without Prednisone in Treating Patients With Metastatic or Recurrent Thymoma
Studying Thymic carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Eastern Cooperative Oncology Group
- Principal Investigator
- David S. Ettinger, MDSidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Intervention
- octreotide acetate(drug)
- Enrollment
- 38 enrolled
- Eligibility
- 18-120 years · All sexes
- Timeline
- 1998
Study locations (25)
- Veterans Affairs Medical Center - Palo Alto, Palo Alto, California, United States
- Stanford University Medical Center, Stanford, California, United States
- CCOP - Colorado Cancer Research Program, Inc., Denver, Colorado, United States
- Sylvester Cancer Center, University of Miami, Miami, Florida, United States
- Emory University Hospital - Atlanta, Atlanta, Georgia, United States
- Veterans Affairs Medical Center - Atlanta (Decatur), Decatur, Georgia, United States
- Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States
- Veterans Affairs Medical Center - Lakeside Chicago, Chicago, Illinois, United States
- CCOP - Carle Cancer Center, Urbana, Illinois, United States
- Veterans Affairs Medical Center - Indianapolis (Roudebush), Indianapolis, Indiana, United States
- CCOP - Cedar Rapids Oncology Project, Cedar Rapids, Iowa, United States
- Johns Hopkins Oncology Center, Baltimore, Maryland, United States
- New England Medical Center Hospital, Boston, Massachusetts, United States
- CCOP - Kalamazoo, Kalamazoo, Michigan, United States
- CCOP - Metro-Minnesota, Saint Louis Park, Minnesota, United States
- +10 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00003283 on ClinicalTrials.govOther trials for Thymic carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07132918HEARTS Trial for Thoracic CancersUniversity of Wisconsin, Madison
- RECRUITINGPHASE2NCT06838910Tislelizumab Combined With Anlotinib as Second-line Therapy in Thymoma and Thymic CarcinomaThe First Affiliated Hospital with Nanjing Medical University
- RECRUITINGNANCT06692062Hypofractionated Radiotherapy for Thymic Epithelial TumorsRongrong Zhou
- RECRUITINGPHASE2NCT06248515A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial TumorsGeorgetown University
- RECRUITINGPHASE3NCT06402708Postoperative Adjuvant Chemotherapy for Thymic Cancer (FUSCC-Thymic 3)Fudan University
- RECRUITINGPHASE3NCT02633514Adjuvant Treatment for Incomplete Resection Thymoma or Thymic CarcinomaFudan University
- RECRUITINGPHASE2NCT05832827First-line CBDCA/PTX/LEN/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas (Artemis)National Cancer Center, Japan
- RECRUITINGNCT06301945Artificial Intelligence Prediction Tool in Thymic Epithelial TumorsErasmus Medical Center